We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Danaher Corporation | NYSE:DHR | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 1.41 | 0.57% | 248.25 | 249.73 | 247.59 | 248.45 | 1,787,707 | 01:00:00 |
From May 2021 to May 2024
By Colin Kellaher
Danaher Corp. on Thursday said it agreed to pay about $9.6 billion in cash to buy Aldevron LLC, a contract development and manufacturing organization that specializes in making biologics for the pharmaceutical and biotechnology industry.
The Washington science and technology conglomerate said it plans to fund the deal with cash on hand and/or the issuance of commercial paper.
Stockholm-based EQT AB in 2019 acquired a majority stake in Aldevron from fellow private-equity firm TA Associates, which retained a minority interest.
Danaher said Aldevron, based in Fargo, N.D., employs about 600 people and makes plasmid DNA, mRNA and proteins. The company has recently been working with Moderna Inc. to support that company's Covid-19 vaccine and other programs in its clinical pipeline.
Aldevron, which serves biotechnology and pharmaceutical customers across research, clinical and commercial applications, will operate as a standalone company and brand within Danaher's life-sciences segment.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 17, 2021 09:39 ET (13:39 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Danaher Chart |
1 Month Danaher Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
